Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 6/20 | 0.40 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.40 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.40 |
| ▸ | AR | P10275 | 2/20 | 0.40 |
| ▸ | AVPR1B | P47901 | 1/20 | 0.39 |
| ▸ | IP6K1 | Q92551 | 2/20 | 0.38 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.35 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.34 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.33 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.33 |
| ▸ | IDH1 | O75874 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.33 |
| ▸ | CDK1 | P06493 | 1/20 | 0.33 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.33 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | GSK3A | P49840 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16837188 | 1.00 | PGR (0.40) | PGRNR3C2NR3C1ARAVPR1B | |
| SCHEMBL1479564 | 0.85 | AVPR1B (0.39) | PGRNR3C2NR3C1ARAVPR1B | |
| SCHEMBL1479873 | 0.85 | AVPR1B (0.42) | PGRNR3C2NR3C1ARAVPR1B | |
| SCHEMBL1590596 | 0.84 | IDO1 (0.40) | PGRIP6K1 | |
| SCHEMBL75334 | 0.84 | PGR (0.40) | PGRAVPR1BAURKBTRPV4 | |
| SCHEMBL1588454 | 0.82 | IP6K1 (0.37) | PGRNR3C2NR3C1ARAVPR1B | |
| SCHEMBL1479795 | 0.81 | IP6K1 (0.41) | PGRNR3C2NR3C1ARAVPR1B | |
| SCHEMBL16837199 | 0.81 | IP6K1 (0.41) | PGRNR3C2NR3C1ARAVPR1B | |
| SCHEMBL1480622 | 0.80 | IP6K1 (0.39) | PGRNR3C2NR3C1ARAVPR1B | |
| SCHEMBL8049691 | 0.79 | IP6K1 (0.40) | PGRNR3C2NR3C1ARAVPR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9840495-B2 | Oxindole derivatives carrying a piperidyl-substituted azetidinyl substituent and use thereof for treating vasopressine-related diseases | AbbVie Deutschland GmbH & Co. KG (DE) | 2017-12-12 | — | — | US | disclosed |
| US-20170008875-A1 | OXINDOLE DERIVATIVES CARRYING A PIPERIDYL-SUBSTITUTED AZETIDINYL SUBSTITUENT AND USE THEREOF FOR TREATING VASOPRESSINE-RELATED DISEASES | AbbVie Deutschland GmbH & Co. KG (DE) | 2017-01-12 | — | — | US | disclosed |
| US-20150352110-A1 | SUBSTITUTED OXINDOLE DERIVATIVES AND THEIR USE AS VASOPRESSIN RECEPTOR LIGANDS | ABBVIE DEUTSCHLAND (DE) | 2015-12-10 | — | — | US | disclosed |
| WO-2015091931-A1 | OXINDOLE DERIVATIVES CARRYING A PIPERIDYL-SUBSTITUTED AZETIDINYL SUBSTITUENT AND USE THEREOF FOR TREATING VASOPRESSINE-RELATED DISEASES | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-06-25 | — | — | WO | disclosed |
| US-20140378471-A1 | SUBSTITUTED OXINDOLE DERIVATIVES AND THEIR USE AS VASOPRESSIN RECEPTOR LIGANDS | ABBOTT GMBH & CO. KG (DE) | 2014-12-25 | — | — | US | disclosed |
| US-8859557-B2 | Substituted oxindole derivatives and their use as vasopressin receptor ligands | ABBOTT GMBH & CO. KG (DE) | 2014-10-14 | — | — | US | disclosed |
| US-8815868-B2 | Substituted oxindole derivatives and their use as vasopressin receptor ligands | ABBOTT GMBH & CO. KG (DE) | 2014-08-26 | — | — | US | disclosed |
| EP-2114923-B1 | SUBSTITUTED OXINDOLE DERIVATIVES AND THEIR USE AS VASOPRESSIN RECEPTOR LIGANDS | ABBOTT GMBH & CO KG (DE) | 2014-08-06 | — | — | EP | disclosed |
| CN-101611028-B | Substituted oxindole derivatives and their use as vasopressin receptor ligands | ABBOTT GMBH & CO KG | 2013-09-11 | — | — | CN | disclosed |
| EP-2114922-B1 | SUBSTITUTED OXINDOLE DERIVATIVE AND ITS USE AS A VASOPRESSIN RECEPTOR MODULATOR | ABBOTT GMBH & CO KG (DE) | 2013-04-24 | — | — | EP | disclosed |
| US-20110124658-A1 | SUBSTITUTED OXINDOLE DERIVATIVES AND THEIR USE AS VASOPRESSIN RECEPTOR LIGANDS | ABBOTT GMBH & CO. KG (DE) | 2011-05-26 | — | — | US | disclosed |
| CN-101611028-A | The oxindole derivatives that replaces and they are used as the purposes of vasopressin receptor ligands | ABBOTT GMBH & CO KG (DE) | 2009-12-23 | — | — | CN | disclosed |
| EP-2114921-A1 | SUBSTITUTED OXINDOLE DERIVATIVE AND ITS USE AS A VASOPRESSIN RECEPTOR LIGAND | Abbott GmbH & Co. KG (DE) | 2009-11-11 | — | — | EP | disclosed |
| EP-2114923-A1 | SUBSTITUTED OXINDOLE DERIVATIVES AND THEIR USE AS VASOPRESSIN RECEPTOR LIGANDS | Abbott GmbH & Co. KG (DE) | 2009-11-11 | — | — | EP | disclosed |
| EP-2114922-A1 | SUBSTITUTED OXINDOLE DERIVATIVE AND ITS USE AS A VASOPRESSIN RECEPTOR MODULATOR | Abbott GmbH & Co. KG (DE) | 2009-11-11 | — | — | EP | disclosed |
| WO-2009071691-A2 | OXINDOLE DERIVATIVES AND THE USE THEREOF AS A MEDICATION | ABBOTT GMBH & CO. KG (DE) | 2009-06-11 | — | — | WO | disclosed |
| WO-2008080971-A1 | SUBSTITUTED OXINDOLE DERIVATIVE AND ITS USE AS A VASOPRESSIN RECEPTOR LIGAND | ABBOTT GMBH & CO. KG (DE) | 2008-07-10 | — | — | WO | disclosed |
| WO-2008080970-A1 | SUBSTITUTED OXINDOLE DERIVATIVE AND ITS USE AS A VASOPRESSIN RECEPTOR LIGAND | ABBOTT GMBH & CO. KG (DE) | 2008-07-10 | — | — | WO | disclosed |
| WO-2008080973-A1 | SUBSTITUTED OXINDOLE DERIVATIVES AND THEIR USE AS VASOPRESSIN RECEPTOR LIGANDS | ABBOTT GMBH & CO. KG (DE) | 2008-07-10 | — | — | WO | disclosed |
| WO-2008080972-A1 | SUBSTITUTED OXINDOLE DERIVATIVE AND ITS USE AS A VASOPRESSIN RECEPTOR MODULATOR | ABBOTT GMBH & CO. KG (DE) | 2008-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378471-A1 | SUBSTITUTED OXINDOLE DERIVATIVES AND THEIR USE AS VASOPRESSIN RECEPTOR LIGANDS | AVPR2, AVPR1B, AVPR1A | PGR 548/4885NR3C2 63/4885NR3C1 358/4885 |
| US-20150352110-A1 | SUBSTITUTED OXINDOLE DERIVATIVES AND THEIR USE AS VASOPRESSIN RECEPTOR LIGANDS | AVPR2, AVPR1B, AVPR1A | PGR 548/4885NR3C2 63/4885NR3C1 358/4885 |
| US-20170008875-A1 | OXINDOLE DERIVATIVES CARRYING A PIPERIDYL-SUBSTITUTED AZETIDINYL SUBSTITUENT AND USE THEREOF FOR TREATING VASOPRESSINE-RELATED DISEASES | AVPR2, AVPR1B, AVPR1A | PGR 609/4885NR3C2 90/4885NR3C1 878/4885 |
| US-20110124658-A1 | SUBSTITUTED OXINDOLE DERIVATIVES AND THEIR USE AS VASOPRESSIN RECEPTOR LIGANDS | AVPR2, AVPR1B, AVPR1A | PGR 548/4885NR3C2 63/4885NR3C1 358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.